These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 23906938

  • 1. Treatment with everolimus is associated with a procoagulant state.
    Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [Abstract] [Full Text] [Related]

  • 2. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators.
    Lancet; 2011 Mar 05; 377(9768):837-47. PubMed ID: 21334736
    [Abstract] [Full Text] [Related]

  • 3. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F, Cappelli G, Mori G, Granito M, Magnoni G, Botta C, Solazzo A, Fontana F, Baisi A, Bonucchi D.
    Transplant Proc; 2014 Sep 05; 46(7):2263-8. PubMed ID: 25242766
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators.
    Transplantation; 2011 Aug 27; 92(4):410-8. PubMed ID: 21697773
    [Abstract] [Full Text] [Related]

  • 7. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov 27; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 8. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
    Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M.
    Transplant Proc; 2006 Nov 27; 38(1):105-7. PubMed ID: 16504676
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D, Molina-Andujar A, Montagud-Marrahi E, Revuelta I, Rovira J, Ventura-Aguiar P, Piñeiro GJ, De Sousa-Amorim E, Esforzado N, Cofán F, Torregrosa JV, Ugalde-Altamirano J, Ricart MJ, Centellas-Pérez FJ, Solè M, Martorell J, Ríos J, Campistol JM, Diekmann F, Oppenheimer F.
    Transplantation; 2020 Aug 27; 104(8):1686-1694. PubMed ID: 32732848
    [Abstract] [Full Text] [Related]

  • 13. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A, Tordera D, de la Sen ML, Jiménez L, Mas P, Muñoz C, Olivares J.
    Nefrologia; 2012 Aug 27; 32(5):631-8. PubMed ID: 23013949
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
    Lehner F, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Witzke O, Wolters HH, Suwelack B, Klehr HU, Stangl M, Hauser IA, Nadalin S, Porstner M, May C, Paulus EM, Sommerer C, ZEUS Study Investigators.
    Transpl Int; 2014 Nov 27; 27(11):1192-204. PubMed ID: 25070687
    [Abstract] [Full Text] [Related]

  • 15. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov 27; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 16. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 17. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG, Tanios BY, Itani HS, Lotfi T, McMullan C, Gabardi S, Akl EA, Azzi JR.
    Clin J Am Soc Nephrol; 2017 Aug 07; 12(8):1321-1336. PubMed ID: 28576905
    [Abstract] [Full Text] [Related]

  • 18. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial.
    van Dijk M, van Roon AM, Said MY, Bemelman FJ, Homan van der Heide JJ, de Fijter HW, de Vries APJ, Bakker SJL, Sanders JSF.
    Transpl Int; 2018 Dec 07; 31(12):1380-1390. PubMed ID: 30106185
    [Abstract] [Full Text] [Related]

  • 19. The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients.
    Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M.
    Transplantation; 1996 Sep 27; 62(6):828-30. PubMed ID: 8824484
    [Abstract] [Full Text] [Related]

  • 20. Proteinuria associated with mTOR inhibitors after kidney transplant.
    Guney M, Sahin G, Yilmaz B, Canbakan M, Gucun M, Kayatas K, Eren P, Titiz I.
    Exp Clin Transplant; 2014 Dec 27; 12(6):539-42. PubMed ID: 25489805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.